Competing risks data in clinical oncology
Competing risks data analysis plays a critical role in the evaluation of clinical utility of specific cancer treatments and can inform the development of future treatment approaches. Although competing risks data are ubiquitous in cancer studies, competing risks data are infrequently recognized and...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1360266/full |
| _version_ | 1797224283694432256 |
|---|---|
| author | Haesook Teresa Kim |
| author_facet | Haesook Teresa Kim |
| author_sort | Haesook Teresa Kim |
| collection | DOAJ |
| description | Competing risks data analysis plays a critical role in the evaluation of clinical utility of specific cancer treatments and can inform the development of future treatment approaches. Although competing risks data are ubiquitous in cancer studies, competing risks data are infrequently recognized and competing risks data analysis is not commonly performed. Consequently, efficacy of specific treatments is often incompletely and inaccurately presented and thus study results may be interpreted improperly. In the present article, we aim to enhance awareness of competing risks data and provide a general overview and guidance on competing risks data and its analysis using cancer clinical studies. |
| first_indexed | 2024-04-24T13:50:40Z |
| format | Article |
| id | doaj.art-a6dc86c4a82c4ef78faa9f7a3bb11d22 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T13:50:40Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a6dc86c4a82c4ef78faa9f7a3bb11d222024-04-04T05:04:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-04-011410.3389/fonc.2024.13602661360266Competing risks data in clinical oncologyHaesook Teresa KimCompeting risks data analysis plays a critical role in the evaluation of clinical utility of specific cancer treatments and can inform the development of future treatment approaches. Although competing risks data are ubiquitous in cancer studies, competing risks data are infrequently recognized and competing risks data analysis is not commonly performed. Consequently, efficacy of specific treatments is often incompletely and inaccurately presented and thus study results may be interpreted improperly. In the present article, we aim to enhance awareness of competing risks data and provide a general overview and guidance on competing risks data and its analysis using cancer clinical studies.https://www.frontiersin.org/articles/10.3389/fonc.2024.1360266/fullcompeting risksdata analysisclinical utilitycancer treatmentefficacy |
| spellingShingle | Haesook Teresa Kim Competing risks data in clinical oncology Frontiers in Oncology competing risks data analysis clinical utility cancer treatment efficacy |
| title | Competing risks data in clinical oncology |
| title_full | Competing risks data in clinical oncology |
| title_fullStr | Competing risks data in clinical oncology |
| title_full_unstemmed | Competing risks data in clinical oncology |
| title_short | Competing risks data in clinical oncology |
| title_sort | competing risks data in clinical oncology |
| topic | competing risks data analysis clinical utility cancer treatment efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1360266/full |
| work_keys_str_mv | AT haesookteresakim competingrisksdatainclinicaloncology |